Curis (NASDAQ:CRIS) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Curis (NASDAQ:CRIS) in a research report sent to investors on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their target price on Curis from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, March 31st.

Curis Trading Up 10.3 %

NASDAQ:CRIS opened at $1.29 on Monday. The company has a market capitalization of $10.95 million, a P/E ratio of -0.17 and a beta of 3.51. Curis has a 12 month low of $1.02 and a 12 month high of $16.99. The firm has a fifty day simple moving average of $2.51 and a 200-day simple moving average of $3.51.

Curis (NASDAQ:CRIS) last issued its earnings results on Monday, March 31st. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.11. The company had revenue of $2.70 million during the quarter, compared to analyst estimates of $2.04 million. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. Equities analysts forecast that Curis will post -7.12 EPS for the current year.

Institutional Investors Weigh In On Curis

Hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC purchased a new position in shares of Curis during the 4th quarter valued at about $35,000. Millennium Management LLC raised its position in Curis by 92.6% during the fourth quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 12,287 shares in the last quarter. Focused Wealth Management Inc lifted its holdings in Curis by 9.5% in the fourth quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock valued at $181,000 after acquiring an additional 5,138 shares during the period. Geode Capital Management LLC boosted its position in Curis by 27.3% in the 4th quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock worth $254,000 after purchasing an additional 17,820 shares in the last quarter. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of Curis during the 4th quarter worth approximately $607,000. 29.97% of the stock is owned by hedge funds and other institutional investors.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.